- Home
- KULR vs ARCT Comparison
KULR vs ARCT Comparison
Compare KULR & ARCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KULR
- ARCT
- Stock Information
- Founded
- KULR 2013
- ARCT 2013
- Country
- KULR United States
- ARCT United States
- Employees
- KULR N/A
- ARCT N/A
- Industry
- KULR Electrical Products
- ARCT Biotechnology: Pharmaceutical Preparations
- Sector
- KULR Technology
- ARCT Health Care
- Exchange
- KULR Nasdaq
- ARCT Nasdaq
- Market Cap
- KULR 275.2M
- ARCT 298.3M
- IPO Year
- KULR N/A
- ARCT N/A
- Fundamental
- Price
- KULR $1.37
- ARCT $10.98
- Analyst Decision
- KULR Strong Buy
- ARCT Strong Buy
- Analyst Count
- KULR 2
- ARCT 7
- Target Price
- KULR $5.00
- ARCT $57.80
- AVG Volume (30 Days)
- KULR 7.2M
- ARCT 380.5K
- Earning Date
- KULR 05-19-2025
- ARCT 05-12-2025
- Dividend Yield
- KULR N/A
- ARCT N/A
- EPS Growth
- KULR N/A
- ARCT N/A
- EPS
- KULR N/A
- ARCT N/A
- Revenue
- KULR $10,737,481.00
- ARCT $152,310,000.00
- Revenue This Year
- KULR $87.77
- ARCT N/A
- Revenue Next Year
- KULR $102.93
- ARCT $44.93
- P/E Ratio
- KULR N/A
- ARCT N/A
- Revenue Growth
- KULR 9.23
- ARCT N/A
- 52 Week Low
- KULR $0.20
- ARCT $8.04
- 52 Week High
- KULR $5.49
- ARCT $45.00
- Technical
- Relative Strength Index (RSI)
- KULR 53.36
- ARCT 42.59
- Support Level
- KULR $1.20
- ARCT $10.70
- Resistance Level
- KULR $1.36
- ARCT $13.10
- Average True Range (ATR)
- KULR 0.08
- ARCT 0.83
- MACD
- KULR 0.02
- ARCT -0.05
- Stochastic Oscillator
- KULR 75.93
- ARCT 9.46
About KULR KULR Technology Group Inc.
KULR Technology Group Inc develops and commercializes high-performance thermal management technologies for electronics, batteries, and other components. The company is focused on targeting the following applications: electric vehicles and autonomous driving systems; artificial intelligence and Cloud computing; energy storage; and 5G communication technologies.
About ARCT Arcturus Therapeutics Holdings Inc.
Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on opportunities in rare diseases with a current focus on liver and respiratory diseases. It operates in one business segment, which includes all activities related to the discovery, development and commercialization of messenger RNA medicines. The company's pipeline includes LUNAR-OTC, LUNAR-CF, LUNAR-FLU, and LUNAR-COV19.